References
- ATS/ERSAmerican Thoracic Society/European Respiratory Society statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiencyAm J Respir Crit Care Med200316881890014522813
- StollerJKAboussouanLSA review of α1-antitrypsin deficiencyAm J Respir Crit Care Med2012185324625921960536
- LarssonCNatural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi ZActa Med Scand19782045345351309708
- TanashHANilssonPMNilssonJAPiitulainenEClinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ)Thorax200863121091109518682522
- TanashHAEkströmMRönmarkELindbergAPiitulainenESurvival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habitsEur Respir J2017503170019828889108
- SvegerTLiver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infantsN Engl J Med197629424131613211083485
- SvegerTPiitulainenEArboreliusMLung function in adolescents with alpha1-antitrypsin deficiencyActa Paediatr19948311117011737841733
- SvegerTPiitulainenEArboreliusMα1-Antitrypsin deficiency: clinical features and lung function in 18-year-old adolescents with α1-antitrypsin deficiencyActa Paediatr19958478158167549305
- PiitulainenESvegerTRespiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ)Thorax200257870570812149531
- PiitulainenECarlsonJOhlssonKSvegerTAlpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studiesChest200512842076208116236857
- BernspångESvegerTPiitulainenERespiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiencyRespir Med200710191971197617532199
- TanashHANystedt-DüzakinMMonteroLCSvegerTPiitulainenEThe Swedish α1-Antitrypsin screening study: health status and lung and liver function at age 34Ann Am Thorac Soc201512680781225803183
- PiitulainenEMonteroLCNystedt-DüzakinMLung function and CT densitometry in subjects with alpha-1-Antitrypsin deficiency and healthy controls at 35 years of ageCOPD201512216216725280185
- PiitulainenEMostafaviBTanashHAHealth status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 yearsInt J Chron Obstruct Pulmon Dis20171249550028203073
- MostafaviBDiazSTanashHAPiitulainenELiver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of ageMedicine20179612e618028328804
- MostafaviBDiazSPiitulainenEStoelBCWollmerPTanashHALung function and CT lung densitometry in 37–39 year-old individuals with alpha-1-antitrypsin deficiencyInt J Chron Obstruct Pulmon Dis2018133689369830510411
- BrantlyMLPaulLDMillerBHFalkRTWuMCrystalRGClinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptomsAm Rev Respir Dis198813823273363264124
- ErikssonSCarlsonJVelezRRisk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiencyN Engl J Med1986314127367393485248
- TanashHAEkströmMWagnerPPiitulainenECause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in SwedenInt J Chron Obstruct Pulmon Dis2016111663166927555756
- GreenCEVayalapraSHampsonJAMukherjeeDStockleyRATurnerAMPiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPDThorax2015701093994526141072
- O’BrienMLBuistNRMurpheyWHNeonatal screening for alpha1-antitrypsin deficiencyJ Pediatr197892610061010307054